

# A randomised trial evaluating the vascular endothelial growth factor inhibitor, bevacizumab (AVASTin®), as adjuvant therapy following resection of American Joint Committee on Cancer (AJCC) stage IIB (T4aN0M0), IIC (T4bN0M0) and III (TxN1-2M0) cutaneous Melanoma

<b>Submission date</b> 03/01/2007	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 30/03/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 26/10/2018	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

<http://www.cancerhelp.org.uk/trials/a-trial-looking-at-bevacizumab-after-surgery-for-melanoma-skin-cancer>

## Contact information

### Type(s)

Scientific

### Contact name

Dr Philippa Corrie

### Contact details

Oncology Centre  
Box 193  
Addenbrooke's Hospital  
Hills Road  
Cambridge  
United Kingdom  
CB2 0QQ  
+44 (0)1223 216083  
[pippa.corrie@addenbrookes.nhs.uk](mailto:pippa.corrie@addenbrookes.nhs.uk)

# Additional identifiers

## Clinical Trials Information System (CTIS)

2006-005505-64

## Protocol serial number

2006-005505-64

# Study information

## Scientific Title

A randomised trial evaluating the vascular endothelial growth factor inhibitor, bevacizumab (AVASTin®), as adjuvant therapy following resection of American Joint Committee on Cancer (AJCC) stage IIB (T4aN0M0), IIC (T4bN0M0) and III (TxN1-2M0) cutaneous Melanoma

## Acronym

AVAST-M

## Study objectives

To determine the overall survival of patients treated with bevacizumab, compared with standard observation after resection of high risk melanoma.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Oxford C Multi-centre Research Ethics Committee, ref: 07/Q1606/15 - approval pending

## Study design

Randomised phase III multi-centre prospective clinical trial

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Cutaneous melanoma

## Interventions

After resection of the high risk melanoma, patients will be given 7.5 mg per Kg bevacizumab by Intravenous (IV) infusion (30 minutes +/- 10 minutes). Bevacizumab infusions will be administered every three weeks for 51 weeks (maximum of 17 infusions) versus standard observation. The following samples will be taken/performed:

1. Venepuncture: blood samples will be taken at each visit, observation arm frequency equivalent to routine clinical care (n = 11), bevacizumab arm frequency higher (n = 33). The volume of blood taken on nine occasions in all will be greater, to collect blood for research purposes
2. Tissue/bodily sample: urinalysis at baseline in all patients, then at intervals over ten years

for patients receiving bevacizumab

3. Biopsy material: excision biopsy of accessible recurrent tumour tissue and adjacent normal tissue from consenting patients
4. Imaging Investigations with radiation: Computed Tomography (CT) (or Magnetic Resonance Imaging [MRI]) scan of head pre-randomisation
5. Day-case attendance: patients receiving bevacizumab will attend an appropriate clinic for drug administration
6. Questionnaire: quality of life questionnaire

## **Intervention Type**

Drug

## **Phase**

Phase III

## **Drug/device/biological/vaccine name(s)**

Bevacizumab

## **Primary outcome(s)**

Overall survival

## **Key secondary outcome(s)**

1. Disease-free interval
2. Distant metastasis-free interval
3. Quality of life
4. Safety and toxicity

## **Completion date**

05/03/2017

# **Eligibility**

## **Key inclusion criteria**

1. Written informed consent
2. Age more than or equal to 18 years
3. Able to comply with the protocol
4. Patients with histological confirmation of completely resected American Joint Committee on Cancer (AJCC) stage IIB (T4aN0M0), IIC (T4bN0M0) and III (TxN1-2M0) cutaneous melanoma
5. Patients may or may not have undergone sentinel lymph node dissection and/or elective lymph node dissection
6. Patients must be randomised within 12 weeks of completing primary surgery (wide local excision and lymphadenectomy)
7. Eastern Cooperative Oncology Group (ECOG) performance status zero to one
8. Life expectancy more than or equal to six months
9. Adequate haematological function:
  - a. Absolute Neutrophil Count (ANC) more than or equal to  $1.5 \times 10^9/L$ , and
  - b. platelet count more than or equal to  $100 \times 10^9/L$ , and
  - c. haemoglobin more than or equal to 9 g/dL (may be transfused to maintain or exceed this level)
10. Adequate liver function:
  - a. total bilirubin less than  $1.5 \times$  Upper Limit of Normal (ULN), and
  - b. Aspartate aminotransferase (AST), and/or Alanine aminotransferase (ALT) less than  $2 \times$  ULN

**11. Adequate renal function:**

- a. serum creatinine less than or equal to 1.25 x ULN or calculated creatinine clearance more than or equal to 50 mL/min, and
- b. urine dipstick for proteinuria less than 2+. Patients discovered to have more than or equal to 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate less than or equal to 1 g of protein in 24 hours
- c. International Normalised Ratio (INR) less than or equal to 1.5 and Partial Prothrombin Time (PPT) less than or equal to 1.5 x ULN

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Any evidence of distant or non-regional lymph node metastases
2. Evidence of Central Nervous System (CNS) metastases, even if previously treated
3. Incomplete surgical resection of the disease
4. Prior chemotherapy, immunotherapy, hormonal therapy or radiotherapy for melanoma
5. Any surgery (including open biopsy, but excluding insertion of an indwelling catheter), or significant traumatic injury within 28 days prior to randomisation, or anticipation of the need for surgery during study treatment
6. Current or recent (within seven days of randomisation) use of aspirin (more than 325 mg/day)
7. Current or recent (within seven days of randomisation) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes. Prophylactic use of anticoagulants is allowed
8. History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding
9. Uncontrolled hypertension (blood pressures: systolic more than 150 mmHg and/or diastolic more than 100 mmHg)
10. Clinically significant (i.e. active) cardiovascular disease for example Coronary Vascular Accident (CVA) (less than or equal to six months before randomisation), myocardial infarction (less than or equal to six months before randomisation), unstable angina, congestive heart failure New York Heart Association (NYHA) class more than or equal to II, serious cardiac arrhythmia requiring medication during the study and might interfere with regularity of the study treatment, or not controlled by medication
11. Non-healing wound, active peptic ulcer or bone fracture
12. History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within six months of randomisation
13. Pregnant or breast-feeding females
14. Women with an intact uterus (unless amenorrhoeic for the last 24 months) not using, or do not agree to use, effective non-hormonal means of contraception (intrauterine contraceptive

device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) if randomised to the treatment arm and for a period of six months following the last administration of bevacizumab. Men who do not agree to use effective contraception if randomised to the treatment arm and for a period of 60 days following the last administration of bevacizumab

15. Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to randomisation

16. Known hypersensitivity to bevacizumab or any of its excipients

17. Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications

18. Any condition, which, in the opinion of the investigator, might interfere with the safety of the patient or evaluation of the study objectives

**Date of first enrolment**

05/03/2007

**Date of final enrolment**

05/03/2017

## **Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Addenbrooke's Hospital**

Cambridge

United Kingdom

CB2 0QQ

## **Sponsor information**

**Organisation**

Cambridge University Hospitals NHS Foundation Trust (UK)

**ROR**

<https://ror.org/04v54gj93>

## **Funder(s)**

**Funder type**

Charity

**Funder Name**

Cancer Research UK (ref: C7535/A6408) (UK)

**Alternative Name(s)**

CR\_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Other non-profit organizations

**Location**

United Kingdom

## Results and Publications

**Individual participant data (IPD) sharing plan****IPD sharing plan summary****Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/05/2014		Yes	No
<a href="#">Results article</a>	results	01/02/2018		Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes
<a href="#">Plain English results</a>				No	Yes